IMAP India advises Shreya Lifesciences in its sale of Digeplex brand to Piramal Enterprises

Shreya Life Sciences is a Pharmaceutical Organisation involved in Research, Manufacturing, Marketing, Sales and Distribution of Medicinal Formulations and Products. Beginning its journey in 1995 in Russia, Shreya Life Sciences started as a pharmaceutical distributing and marketing company. In the course of over two decades, Shreya Life Sciences has pioneered innovations and achieved milestones in Acquisition of companies/ brands,

Primal Enterprise is conglomerate with strong presence in pharma market. Piramal Enterprises Limited made its foray into the Over-the-Counter (OTC) market after acquiring Saridon from Roche and Lacto Calamine from Duphar in the early 1990s. This business has a well-positioned product portfolio with a purpose to improve people’s lives by offering products that address their routine-disruptors. It has a diverse product range of 21 brands across categories such as Skin Care, Vitamins & Nutrition, Antacids, Analgesics, Gastro-intestinal and Baby-Care.

This acquisition will help Primal Enterprise expand its its gastro-intestinal product portfolio. “We believe Digeplex and its associated brands are a strategic fit for our portfolio that will help us move closer towards our stated objective,” executive director Nandini Piramal said.

Gastro-intestinal market comprising constipation, diarrhoea and appetite stimulant categories in India is estimated to be over USD 2 billion and growing , is a Rs 13,000-crore opportunity which has been clipping at 11 per cent every year.